FIELD : medicine.SUBSTANCE : invention relates to the field of medicine, in particular to oncology, and is intended to predict non-metastatic survival in patients with breast cancer. Tumor tissue is taken from patients during surgery after neoadjuvant chemotherapy (NAC) with subsequent isolation of RNA. Carry out quantitative PCR in real time, determine the level of expression of OCT3, LAT, and LMNB2 genes using TaqMan technology using specific primers and samples. OCT3, LAT, and LMNB2 gene expression is assessed using the Pfaff1 method relative to the GAPDH gene-referee. At the OCT3 expression level below 1.3 standard units, LAT and LMNB2 expression level below 1 standard unit, determine their hypoexpression. At the level of values above these indicators, determine the overexpression. With simultaneous overexpression of OCT3, LAT, LMNB2 genes in the residual tumor, an unfavorable outcome is predicted with a probability of 69?%. When hypoexpression at least one of the genes predict a favorable outcome with a probability of 94?%.EFFECT : invention provides an increase in the accuracy of determining the outcome of breast cancer in patients receiving NAC through the use of new markers – assessing the expression of three somatic-stem transition genes, OCT3, LAT, and LMNB2, in residual tumor after NAC.1 cl, 1 dwg, 2 ex